Yes, Guts, I feel instinctively that the potential revenues from the various RapiMeds formulations could exceed many expectations. The advantage of starting in Hong Kong is that it functions as a safe, unproblematic testing ground, and that could be much the best way to go for the Chinese authorities, too. I also see plenty of merit in the chart formation and the chief parameters. You point out that being up around 40% on the share price is not bad going for one month. Well, if the next few months turn in similar results, not many here would want to grumble, but we might see an acceleration when the 'handle' phase of the 'cup and handle' is reached. As long as outfits like the "runners" stay away, there is no cause for worry.